What's next for psychedelics after MDMA rejection?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39146407.
- Also identified by DOI 10.1126/science.ads4470.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lykos's failure to win FDA approval for PTSD therapy may accelerate a strategic shift among its competitors.